Two leaders in investment banking released their earnings today before the U.S. market session opened. In pre-market trading, Goldman Sachs' stock is slowly sliding down by about 1.5%, while Morgan Stanley initially rises over 1% but loses gains over time.
Morgan Stanley
The company exceeded investor expectations both in terms of EPS (2.68 vs expected 2.41) and revenues at 17.9 billion dollars compared to the expected 17.7 billion dollars. Net income amounted to 4.4 billion dollars.
This indicates an increase in revenues compared to previous quarters and a slight decrease in profit. The trading and capital management segments performed the best. The board approved a quarterly dividend of $1 per share (unchanged from the last two payments).
MS.US (D1)
Source: xStation5
Goldman Sachs
The company boasts a significant positive surprise in terms of profits. Earnings per share were $14 compared to expectations of $11.6, a quarter-over-quarter increase of about 15%. Revenues were disappointing, amounting to 13.45 billion compared to expectations of 14.5 billion dollars, a decrease of about 10% compared to the previous quarter.
The biggest positive surprises were revenues from asset management and advisory services. Both segments registered a year-over-year growth of 25%.
What is concerning is the increase in operating costs, which rose by 18% year-over-year in Q4.
The board raised the dividend from $4 to $4.5 per share.
GS.US (D1)
Source: xStation5
Daily summary: Wall Street climbs, oil slides 🗽 Is a stronger dollar weighing on Bitcoin?
Euphoria hits semiconductor stocks 📈 KLA Corp hits an all-time high
Natural gas tries to recover after EIA report 🔎
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
